科隆股份 reported revenue of ¥0.32B for the period ended 2026-06-30, +23.5% year on year. Net income was ¥0.01B, a 2.1% net margin on a 12.4% gross margin. The largest revenue line is 聚羧酸减水剂单体 at 43% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.32B | +23.5% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | — |
| Gross margin | 12.4% | Net margin 2.1% |
| Revenue Q/Q | +68.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 聚羧酸减水剂单体 | ¥0.14B | 42.9% |
| 其他精细化学品 | ¥0.07B | 21.0% |
| 苯醚系列产品 | ¥0.06B | 19.8% |
| 其他主营业务 | ¥0.04B | 13.7% |
| 其他(补充) | ¥0.01B | 2.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.28B | 87.6% |
| R&D | ¥0.00B | 1.0% |
| SG&A | ¥0.02B | 7.0% |
| Tax & other | ¥0.00B | 1.2% |
| Item | Amount |
|---|---|
| Total assets | ¥1.03B |
| Total liabilities | ¥0.60B |
| Shareholders' equity | ¥0.42B |
| Equity / assets | 41.1% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | -851% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验 ・ 南华仪器 ・ ST浩丰 ・ 五洋自控
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies